PlasmaBind Docetaxel

Medical

Free · Designed for iPad. Not verified for macOS.

Visualize how free drug exposure changes while total levels appear similar. PlasmaBind Docetaxel is an educational pharmacokinetic (PK) simulation tool designed to visualize how total and free drug exposure may differ under varying physiologic conditions. The app models: • Total plasma exposure (AUC) • Estimated free (unbound) exposure • A simplified site exposure curve It demonstrates how albumin changes can alter free drug exposure even when total exposure appears similar. This application is intended for educational and research visualization purposes only. Important: • Not medical advice • Not a dosing calculator • Not clinical decision support • Not for patient-specific treatment decisions All simulations are simplified and do not account for full clinical variability, including hepatic function, drug interactions, disease state, or chemotherapy regimen complexity. Use for conceptual understanding only.

  • This app hasn’t received enough ratings or reviews to display an overview.

The developer, PlasmaBind Inc., indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy .

  • Data Not Collected

    The developer does not collect any data from this app.

    Privacy practices may vary, for example, based on the features you use or your age. Learn More

    The developer has not yet indicated which accessibility features this app supports. Learn More

    Seller
    PlasmaBind Inc.
    Size
    26.3 MB
    Category
    Medical
    Compatibility
    Requires iOS 15.1 or later.
    • iPhone
      Requires iOS 15.1 or later.
    • iPad
      Requires iPadOS 15.1 or later.
    • iPod touch
      Requires iOS 15.1 or later.
    • Mac
      Requires macOS 12.0 or later and a Mac with Apple M1 chip or later.
    • Apple Vision
      Requires visionOS 1.0 or later.
    Languages
    English
    Age Rating
    4+
    Copyright
    © 2026 PlasmaBind Inc.